Menu
Back to User profile » Prof. Dr. Do Young Kim
Papers published by Prof. Dr. Do Young Kim:
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ
Journal of Hepatocellular Carcinoma 2021, 8:613-623
Published Date: 18 June 2021
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK
Journal of Hepatocellular Carcinoma 2021, 8:467-476
Published Date: 25 May 2021
Current Status of Therapeutic Choice and Feasibility for Patients with Hepatocellular Carcinoma Aged ≥ 70 Years: A Nationwide Cancer Registry Analysis
Rho SY, Lee HW, Kim DY, Kim KS
Journal of Hepatocellular Carcinoma 2021, 8:321-332
Published Date: 30 April 2021
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK
Journal of Hepatocellular Carcinoma 2020, 7:403-412
Published Date: 17 December 2020
Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial
Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH
Drug Design, Development and Therapy 2018, 12:3767-3774
Published Date: 2 November 2018
Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
Kim DY, Kim JH, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, Lee BS, Han BH, Lee HC
Drug Design, Development and Therapy 2017, 11:3145-3152
Published Date: 31 October 2017
Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Lee SH, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH
Journal of Hepatocellular Carcinoma 2015, 2:39-47
Published Date: 28 April 2015
Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma
Lee SH, Kim SU, Jang JW, Bae SH, Lee SH, Kim BK, Park JY, Kim DY, Ahn SH, Han KH
OncoTargets and Therapy 2015, 8:347-356
Published Date: 2 February 2015
Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model
Kim DY, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, Han KH
OncoTargets and Therapy 2013, 6:1463-1469
Published Date: 16 October 2013
Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY
OncoTargets and Therapy 2013, 6:755-759
Published Date: 21 June 2013